Article Text

Download PDFPDF
Adalimumab: a new modality for Behçet’s disease?
  1. J A M van Laar,
  2. T Missotten,
  3. P L A van Daele,
  4. A Jamnitski,
  5. G S Baarsma,
  6. P M van Hagen
  1. Erasmus University Medical Center, Rotterdam, The Netherlands
  1. Correspondence to:
    Dr J A M van Laar
    Room D-419, Erasmus University Medical Center, Gravendijkwal 230, Rotterdam 3015 CE, The Netherlands; j.vanlaar{at}erasmusmc.nl

Statistics from Altmetric.com

Aberrant T cell function,1 subsequently accompanied by increased tumour necrosis factor α (TNFα) levels, induces inflammatory symptoms in patients with Behçet’s disease (BD).2 Subsequently, treatment usually involves T cell-directed immunosuppressive or anti-TNFα treatment in patients with severe disease.3–7 Administration of the new human monoclonal TNFα antibody adalimumab has only been described in three patients with BD with uveitis.8 We analysed the effects of adalimumab on severe and often chronic disease in six heavily pretreated patients with BD in whom immunosuppressive therapy had failed (table 1).

View this table:
Table 1

 Clinical effects in patients treated with infliximab or adalimumab for Behçet’s disease

These patients were treated in the past with infliximab.9 Indications for anti-TNFα treatment …

View Full Text

Footnotes

  • Published Online 23 November 2006

  • Competing interests: PMvH has cooperated in a European study on patients with uveitis treated with infliximab that was sponsored by Centocor. JAMvL and PMvH were in part sponsored to visit the 12th international Behçet’s congress in Lisbon by Abbott BV where JAMvL presented these data to the international investigators on Behçet’s disease.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.